Author
Listed:
- Richard Mark White
(Stem Cell Program and Hematology/Oncology, Children’s Hospital Boston, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Harvard Medical School
Dana Farber Cancer Institute)
- Jennifer Cech
(Stem Cell Program and Hematology/Oncology, Children’s Hospital Boston, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Harvard Medical School)
- Sutheera Ratanasirintrawoot
(Stem Cell Program and Hematology/Oncology, Children’s Hospital Boston, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Harvard Medical School)
- Charles Y. Lin
(Whitehead Institute for Biomedical Research
Massachusetts Institute of Technology)
- Peter B. Rahl
(Whitehead Institute for Biomedical Research)
- Christopher J. Burke
(Stem Cell Program and Hematology/Oncology, Children’s Hospital Boston, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Harvard Medical School)
- Erin Langdon
(Stem Cell Program and Hematology/Oncology, Children’s Hospital Boston, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Harvard Medical School)
- Matthew L. Tomlinson
(School of Biological Sciences, University of East Anglia)
- Jack Mosher
(Center for Stem Cell Biology, University of Michigan, Howard Hughes Medical Institute)
- Charles Kaufman
(Stem Cell Program and Hematology/Oncology, Children’s Hospital Boston, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Harvard Medical School
Dana Farber Cancer Institute)
- Frank Chen
(Harvard University)
- Hannah K. Long
(Cambridge University)
- Martin Kramer
(Genzyme Corporation)
- Sumon Datta
(Stem Cell Program and Hematology/Oncology, Children’s Hospital Boston, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Harvard Medical School)
- Donna Neuberg
(Dana Farber Cancer Institute)
- Scott Granter
(Brigham and Women’s Hospital)
- Richard A. Young
(Whitehead Institute for Biomedical Research
Massachusetts Institute of Technology)
- Sean Morrison
(Center for Stem Cell Biology, University of Michigan, Howard Hughes Medical Institute)
- Grant N. Wheeler
(School of Biological Sciences, University of East Anglia)
- Leonard I. Zon
(Stem Cell Program and Hematology/Oncology, Children’s Hospital Boston, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Harvard Medical School)
Abstract
Oncogenes BRAF(V600E) and SETDB1 in melanoma Transgenic zebrafish carrying the human oncogene BRAF(V600E), the most common mutation in melanoma patients, provide a convenient model for melanoma. Two papers from Leonard Zon and colleagues demonstrate the potential of this system in the study of cancer genetics and in drug development. Ceol et al. screen for genes that cooperate with mutated BRAF, and identify SETDB1 as capable of accelerating melanoma formation in fish. The gene is found in a region that is frequently amplified in human melanomas, and its gene product, SETDB1, is a histone methylating enzyme that is often overexpressed in those melanomas. This work establishes SETDB1 as an important oncogene. White et al. find expression of a gene signature in melanoma-susceptible zebrafish embryos that is indicative of disrupted differentiation of neural crest progenitors. A chemical screen identifies leflunomide, an immunomodulatory drug used to treat rheumatoid arthritis, as an inhibitor of neural crest stem cells. Leflunomide has antimelanoma activity in human melanoma xenografts and might prove useful as an anticancer drug, particularly in combination with BRAF inhibitors.
Suggested Citation
Richard Mark White & Jennifer Cech & Sutheera Ratanasirintrawoot & Charles Y. Lin & Peter B. Rahl & Christopher J. Burke & Erin Langdon & Matthew L. Tomlinson & Jack Mosher & Charles Kaufman & Frank C, 2011.
"DHODH modulates transcriptional elongation in the neural crest and melanoma,"
Nature, Nature, vol. 471(7339), pages 518-522, March.
Handle:
RePEc:nat:nature:v:471:y:2011:i:7339:d:10.1038_nature09882
DOI: 10.1038/nature09882
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:471:y:2011:i:7339:d:10.1038_nature09882. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.